SUVN-G3031

DRUG3 trials

Sponsors

Suven Life Sciences Limited

Conditions

Cognitive DisordersNarcolepsy

Phase 1

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects

CompletedNCT02342041

Suven Life Sciences LimitedCognitive Disorders

Start: 2014-09-30End: 2015-08-31Updated: 2016-10-14

A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects

CompletedNCT02881294

Suven Life Sciences LimitedCognitive Disorders

Start: 2016-08-31End: 2017-09-30Updated: 2017-09-25

Phase 2

A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy

CompletedNCT04072380

Suven Life Sciences LimitedNarcolepsy

Start: 2019-09-21End: 2023-06-13Updated: 2025-01-13

Related Papers

0845 Samelisant (SUVN-G3031) Alleviates Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study

SLEEP2025-05-01

Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

2024-10-301 citations

1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy

SLEEP2024-04-20

0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study

SLEEP2024-04-20

0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy

SLEEP2023-05-013 citations

0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease

SLEEP2023-05-011 citations

0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy

SLEEP2022-05-25

0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy

SLEEP2022-05-25

004 Samelisant (SUVN-G3031), Differentiating features over current treatments of narcolepsy

SLEEP2021-05-011 citations

005 Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist in animal models of sleep disorders

SLEEP2021-05-01

Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.

2020-07-017 citations

0155 SUVN-G3031, A Potent and Selective Histamine H3 Receptor Inverse Agonist - Differentiating Features Over Current Treatments of Narcolepsy

SLEEP2020-04-011 citations

0760 SUVN-G3031, A Potent And Selective Histamine H3 Receptor Inverse Agonist: Safety, Tolerability And Pharmacokinetics Following Single And Multiple Ascending Doses In Healthy Adult Subjects

SLEEP2020-04-01

0759 Phase 2 Proof Of Concept Study Of SUVN-G3031, A Histamine H3 Receptor Inverse Agonist For The Potential Treatment Of Narcolepsy

SLEEP2020-04-01

0072 Preclinical Characterization of SUVN-G3031, a Histamine H3 Receptor Inverse Agonist for the Treatment of Narcolepsy

SLEEP2020-04-01

0008 SUVN-G3031, A Histamine H3 Receptor Inverse Agonist Produces Robust Wake Promoting and Anticataplectic Activity in Orexin Knockout Mice

SLEEP2020-04-01